Clinical Trial Update: Binimetinib and Hydroxychloroquine in Treating Patients With KRAS Mutant Metastatic Pancreatic Cancer [Phase 1]

View source ↗

Summary

Phase 1 clinical trial evaluating the combination of binimetinib and hydroxychloroquine for KRAS-mutant metastatic pancreatic cancer has completed. The study en…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Pancreatic Adenocarcinoma
• Pancreatic Cancer Ajcc V8

Drugs mentioned

• Binimetinib (binimetinib)
• Hydroxychloroquine (hydroxychloroquine)

Snippet

Sponsor: M.D. Anderson Cancer Center | Conditions: Metastatic Pancreatic Adenocarcinoma, Stage IV Pancreatic Cancer AJCC v8 | Phase 1 | Status: COMPLETED